Mesenchymal Stromal Cells
15
1
1
7
Key Insights
Highlights
Success Rate
78% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
13.3%
2 terminated out of 15 trials
77.8%
-8.7% vs benchmark
7%
1 trials in Phase 3/4
0%
0 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (15)
Safety of Topical Mesenchymal Stromal Cell Secretome for Ocular Surface Disease
Effect of Mesenchymal Stem Cells on Healing of Foot Ulcers in Diabetes Patients.
LYell SYndrome MEsenchymal Stromal Cells Treatment
Safety of Locally Delivered Allogeneic Mesenchymal Stromal Cells
ASC - Autism Study
Safety and Efficacy of Expanded Allogeneic AD-MSCs in Patients With Moderate to Severe Psoriasis
Efficacy and Safety of AD-MSCs Plus Calpocitriol Ointment and PSORI-CM01 Granule in Psoriasis Patients
Efficacy and Safety of AD-MSCs Plus Calpocitriol Ointment in Patients With Moderate to Severe Psoriasis
Comparison of PSORI-CM01 Formula vs Gu Ben Hua Yu Formula Combined With AD-MSCs in Psoriasis
MSCs in COVID-19 ARDS
Allogeneic MSC Treatment for Pulmonary Emphysema
Efficacy and Safety of Expanded UCMSCs On Patients With Moderate to Severe Psoriasis
Allogeneic Mesenchymal Stem Cells for Radiation-induced Hyposalivation and Xerostomia/Dry Mouth
Mesenchymal Stem Cells for Radiation-induced Xerostomia
Phase 1 Clinical Trial of PNEUMOSTEM® Treatment in Premature Infants With Intraventricular Hemorrhage